Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DE-117 + tafluprost
- Development stage
- Unknown
- Lead developer
- Santen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
DE-117 + tafluprost is a combination of two ophthalmic agents used for the reduction of intraocular pressure (IOP) in conditions such as primary open-angle glaucoma (POAG) and ocular hypertension (OHT). **DE-117** (omidenepag isopropyl) is a selective prostaglandin E2 (EP2) receptor agonist developed to enhance aqueous humor outflow via the conventional pathway, representing a novel mechanism distinct from traditional prostaglandin analogues[1][2][4]. **Tafluprost** is a prostaglandin F2α analogue that increases uveoscleral outflow of aqueous humor[5]. Both drugs have been studied in monotherapy and combination therapy arms, including a direct clinical trial of DE-117 + tafluprost for POAG and OHT[4].
- Brand names
- EybelisZioptan
- Other names
- omidenepag isopropyltafluprost
02
Targets
PTGER2 (Prostaglandin E2 receptor EP2)PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on DE-117 + tafluprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DE-117 + tafluprost.